Navigation Links
Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast'
Date:8/10/2011

an volunteers treated with Revamilast suggests a good ex-vivo inhibition of the inflammatory marker TNF-α with maximum inhibition upto 93%. Based on these results and animal model data, it is expected that Revamilast would be beneficial in a variety of inflammatory disorders. Additionally, Revamilast does not appear to be metabolized to carcinogenic metabolites (ADCP N-oxide and ADCP N-oxide epoxide); and plasma samples from a Phase 1 study analyzed for such metabolites of Revamilast, showed no levels were detected in human plasma.

With the completion of several Phase I studies, Glenmark has initiated a global Phase IIb trial for Revamilast in patients with Asthma. Glenmark has already received approval from respective authorities in the UK, Poland, India and Czech Republic to conduct Phase IIb studies. Regulatory submissions have also been completed in Russia. The primary objective of this 12-week, double blind, placebo controlled, dose range finding study is to evaluate the effects of Revamilast at three doses on lung function (FEV1) in nearly 450 patients with chronic persistent Asthma.

Glenmark has also initiated another global Phase IIb trial with Revamilast in patients with Rheumatoid Arthritis. Glenmark has already received approval from the MHRA, UK, India, Poland and the Philippines to conduct Phase IIb studies for Rheumatoid Arthritis. Regulatory submissions have also been completed in Sri Lanka. The objective is to determine the efficacy of three doses of Revamilast compared to placebo in the treatment of more than 400 patients with active Rheumatoid Arthritis who showed an inadequate response to methotrexate.

In parallel to these two clinical studies, Glenmark is also conducting various other clinical and non-clinical studies to ensure timely entry into Phase III trials. Glenmark intends to initiate Phase III trials for at least one indication in the second half of FY 2012-13

PDE4 inhibitors (Impact o
'/>"/>

SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Glenmark Announces the Discovery of a Novel Chemical Entity GRC 17536, a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally
2. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
3. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
4. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
5. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
6. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
7. GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
8. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
9. Metabolex Initiates Phase 2 Trial of Arhalofenate
10. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
11. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 AtheroNova Inc. (OTCQB: AHRO) today announced that ... petitions under Chapter 11 of the U.S. Bankruptcy Code in ... , Santa Ana division (the ... cases are expected to be jointly administered. The ... asset sale process, for all or substantially all of its ...
(Date:3/3/2015)... 03, 2015 Genedata, a leading ... and life science research, today announced that Pfizer ... platform for use at Pfizer biopharma research and ... is supporting Pfizer’s global deployment and roll out ... for Therapeutic Innovation (CTI), and Pharmaceutical Sciences groups. ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "RNAi - Technologies, ... Because of its ability to silence any ... adopted as the research tool to discriminate gene function. ... can be designed to target every gene in the ...
(Date:3/3/2015)... -- Elsevier,s DirectCourse online curricula provides ... to comply with new CMS requirements   ... new crosswalk tool to help providers of Home ... service workers as a means to comply with new ... CMS amended the regulations, effective March 17, 2015, ...
Breaking Biology Technology:AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3
... /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS),a leading developer in ... Giese, President and CEO, will present at the,Rodman and Renshaw ... WHEN: Monday May 19th at 11:25 ... Beach Plaza Hotel, Monte Carlo, About Rodman and Renshaw ...
... May 12 NuRx Pharmaceuticals,Inc. (OTC Bulletin Board: NURX ... 9th, the Company,s 1-for-4 reverse stock split became,effective. The ... Bulletin,Board,s Corporate Actions group that, in connection with the ... to NUXP., The reverse stock split will reduce ...
... study supports the potential for QLT,s drug elution technology ... reduce and ... QLT Inc. (NASDAQ: QLTI; TSX:,QLT) announced today results from ... QLT Plug Delivery, Inc., of its punctal plug,drug delivery ...
Cached Biology Technology:BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference 2NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect 2QLT reports initial proof of concept data for punctal plug delivery technology 2QLT reports initial proof of concept data for punctal plug delivery technology 3QLT reports initial proof of concept data for punctal plug delivery technology 4
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Mary had a little lamb, but only once a year. ... of a gene that prompts ewes to breed out of ... frequently. They conducted a simple genetic test to identify ... so-called M allele that other researchers had suspected might be ...
... ANN ARBOR, Mich.---A period of global warming from 53 million ... spurring a biodiversity boom in western North America, researchers from ... week in the Proceedings of the National Academy of ... a vast desert, and a few antelope and deer are ...
... Results of a new study confirm trends that different ... and worse cancer outcomes if they live in the United ... "Hispanics are not all the same with regard ... M.Sc., researcher in the Department of Epidemiology at the University ...
Cached Biology News:Mary had a lot of lambs: Researchers identify way to accelerate sheep breeding 2Climate-caused biodiversity booms and busts in ancient plants and mammals 2Moving to the US increases cancer risk for Hispanics 2Moving to the US increases cancer risk for Hispanics 3
...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
... Focus Long has a long, ... from test tubes, bottles, flasks ... necked vessels. Finnpipette Focus Long ... select, it will be aspirated ...
Biology Products: